Ivarmacitinib alone for rheumatoid arthritis not helped by standard drugs
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests a new pill, ivarmacitinib, for people with moderate-to-severe rheumatoid arthritis who have not gotten enough relief from standard treatments. It aims to reduce joint pain and swelling and improve daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with rheumatoid arthritis.
- You have at least 6 tender or swollen joints, or your disease activity score shows moderate to severe activity.
- You have tried at least one standard drug (like methotrexate or sulfasalazine) for at least 3 months, and it did not work well enough or caused side effects.
- You are not currently taking three or more standard rheumatoid arthritis drugs at once.
- You have never taken a JAK inhibitor (such as tofacitinib or baricitinib) and not responded to it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
This trial tests an investigational drug, ivarmacitinib, to see if it can reduce inflammation and pain in people with polymyalgia rheumatica and help them avoid using steroids. The drug works by blocking certain immune system signals that cause joint and muscle stiffness.
This study tests a pill called Ivarmacitinib (a JAK inhibitor) for people with advanced solid tumors who had to stop immunotherapy because of side effects. The drug aims to calm the immune system and may help you restart cancer treatment.
This study compares a new pill (ivarmacitinib) to standard steroid treatment for people with mild-to-moderate lupus. It aims to see if the new drug can better control symptoms like joint pain and skin rashes while possibly reducing steroid side effects.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.